Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470327 · ClinicalTrials.gov registry record
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
A clinical trial of Idiopathic Pulmonary Fibrosis and Sarcoidosis, sponsored by University of Chicago.
- Recruiting
- Registry status
- 4,000
- Enrollment target
- 1
- Study location
NCT00470327 is a study of Idiopathic Pulmonary Fibrosis and Sarcoidosis that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 4,000 participants, above the 673-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (494% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00470327, a study of Idiopathic Pulmonary Fibrosis and Sarcoidosis, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- 4,000 participants
- Enrollment target
- 1
- Study location
Study Summary
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.
Conditions Studied
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2005-09 |
| Est. Completion | 2030-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00470327
The ClinicalTrials.gov registry entry for NCT00470327 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 673-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (494% higher). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT00470327 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00470327 about?
NCT00470327 is a clinical study titled "A Study of the Natural Progression of Interstitial Lung Disease (ILD)". We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of thes...
What is the current status of trial NCT00470327?
This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 2005-09. Estimated completion is 2030-12.
What conditions does trial NCT00470327 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Sarcoidosis, Interstitial Lung Diseases, Connective Tissue Disorder.
Who is sponsoring clinical trial NCT00470327?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00470327 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.